Modified Coxsackievirus B3 Genome Engineering for Oncolytic Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wild-type Coxsackievirus B3 (CVB3) causes adverse reactions such as inflammation in the pancreas and myocardium, and its oncolytic efficacy against tumors is limited, necessitating a modified form with enhanced safety and tumor-specific targeting.
Innovation Solution
A modified Coxsackievirus B3 is developed by inserting a tissue-specific microRNA target sequence into its genome, specifically between positions 7304 and 7305, and optionally incorporating a region encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance tumor targeting and oncolytic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type CVB3 is used for oncolytic virotherapy, then oncolytic activity against tumors is achieved, but adverse reactions such as inflammation in pancreas and myocardium occur
Solution Approach 1:
The patent applies local quality by inserting tissue-specific microRNA target sequences (miR-217 for pancreas, miR-1 for myocardium) at specific locations in the viral genome. This creates localized suppression of viral replication in specific tissues (pancreas and myocardium) while maintaining oncolytic activity in tumors, thereby reducing adverse reactions without compromising therapeutic efficacy
Solution Approach 2:
The patent uses tissue-specific microRNAs as intermediaries to mediate tissue-specific suppression of viral replication. The microRNA target sequences act as intermediaries that recruit endogenous microRNAs to selectively inhibit viral protein synthesis in specific tissues, providing a mechanism to reduce adverse reactions while preserving tumor-killing activity
2Reliability
If tissue-specific microRNA target sequences are inserted into the viral genome, then safety is improved by suppressing proliferation in specific tissues, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying specific parameters of the viral genome (inserting target sequences at positions 7304-7305 and 7344-7345) to achieve tissue-specific suppression. This targeted modification approach changes the genetic parameters to incorporate microRNA recognition sites while maintaining overall viral structure and function
3Reliability
If multiple microRNA target sequences are inserted to suppress proliferation in multiple tissues, then safety is improved, but virus productivity decreases
Solution Approach 1:
The patent applies local quality by inserting microRNA target sequences at specific locations in the viral genome (positions 7304-7305 and 7344-7345) rather than throughout the entire genome. This localized modification approach suppresses replication only in specific tissues (pancreas and myocardium) while preserving viral productivity in tumor cells and production systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified virus demonstrates improved safety and antitumor effects, with tissue-specific suppression of proliferation and enhanced oncolytic activity, particularly against non-small cell lung cancer, reducing adverse reactions and increasing tumor regression.
Implementation Method 1
inserted with at least one polynucleotide consisting of a target sequence of a tissue-specific microRNA (miRNA)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a mutated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microRNA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.